View Older Stories
-
Stryker (SYK) Declares $0.88 Quarterly Dividend; 1% Yield
-
Stryker (SYK) PT Raised to $454 at Needham
-
Canaccord Genuity Reiterates Buy Rating on Stryker (SYK)
-
Stryker (SYK) Reiterated at Market Outperform by Citizens: Milestones Notched in FY26
-
Stryker (SYK) PT Raised to $412 at BTIG
-
Stryker shares higher as fourth quarter results beat expectations
-
Stryker (SYK) Tops Q4 EPS by 8c, Beats on Revenue; Offers FY26 EPS Guidance
-
Piper Sandler on Stryker (SYK): 'We Encourage Investors to Build Positions in the Name'
-
TD Cowen Assumes Stryker (SYK) at Hold, 'Positive Story Well Understood'
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Who in MedTech could get acquired at this year's healthcare investor conference in SF? Piper answers
-
Raymond James Upgrades Stryker (SYK) to Outperform
-
Increasing unusual put option volume: INVZ BAX FITB EWJ SYK LW BMRN PPLT EQNR HYMC
-
Citizens Upgrades Stryker (SYK) to Market Outperform
-
Stryker (SYK) Raises Quarterly Dividend 4.8% to $0.88; 1% Yield
-
This is the best orthopedics stock to own in 2026, Wolfe says
-
Piper Sandler Shares Medical Technology and Devices Stock Thoughts Post Ortho KOL Call
-
Bernstein Reiterates Outperform Rating on Stryker (SYK) on Bullish Outlook
-
Stryker (SYK) PT Raised to $400 at Truist Securities
-
RBC Capital Sees 'Durable Growth Ahead' for Stryker (SYK)
-
Bernstein on Stryker (SYK): 'Bullish Outlook Focused on Growth and Continued Margin Expansion'
-
Needham Reiterates Buy Rating on Stryker (SYK)
-
Canaccord Genuity Reiterates Buy Rating on Stryker (SYK)
-
Stryker (SYK) PT Lowered to $450 at Bernstein SocGen Group
-
Stryker (SYK) PT Raised to $410 at BTIG
-
Stryker (SYK) Tops Q3 EPS by 6c; raises guidance
-
Evercore Adds Names to TAP Lists
-
Needham: 'we believe that the Section 232 investigation creates a new overhang for the already beleaguered medical device sector'
-
Rothschild Redburn Starts Stryker (SYK) at Neutral
-
This MedTech stock is 'a strong buy under $500': Bernstein
-
Stryker (SYK) Declares $0.84 Quarterly Dividend; 0.9% Yield
-
Stryker (SYK) PT Raised to $415 at Truist After 2Q Beat and Raise
-
Citizens JMP Reiterates Market Perform Rating on Stryker (SYK)
-
Stryker (SYK) PT Raised to $448 at Needham
-
Stryker (SYK) Tops Q2 EPS by 6c; offers guidance
-
Stryker (SYK) Tops Q2 EPS by 6c, raises guidance
-
Stryker's Inari launches new InThrill thrombectomy system for small vessels
-
Stryker (SYK) receives FDA clearance for Incompass Total Ankle System
-
Barclays on Stryker (SYK): 'Under-appreciated Double-Digit Growth Engine'
-
Stryker (SYK) recieves FDA clearance for OptaBlate BVN
-
Stryker (SYK) Declares $0.84 Quarterly Dividend; 0.9% Yield
-
Stryker (SYK) PT Raised to $421 at UBS
-
Stryker (SYK) PT Lowered to $390 at Evercore ISI
-
Stryker (SYK) Tops Q1 EPS by 13c; offers guidance
-
TD Cowen Reiterates Buy Rating on Stryker (SYK), Citing 'Strong Underlying Momentum'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Evercore Adds 7 Names to Tactical Outperform List
-
Stryker (SYK) completes sale of U.S. spinal implants business
-
Stryker (SYK) announces intention to nominate Manny Maceda to board of directors
-
Needham Reiterates Buy Rating on Stryker (SYK)

